$FTH

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size

OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.

Analysts initiated coverage on five companies. Baird rated Hubbell (HUBB) Outperform with a $550 target. BMO rated Nvidia (NVDA) Outperform with a $340 target. Needham rated Faeth Therapeutics (FTH) Buy with a $56 target. Citizens rated Builders FirstSource (BLDR) Market Perform. Cantor Fitzgerald rated Nuvation Bio (NUVB) Overweight.

Faeth Therapeutics (FTH) shares rose 5.8% after the FDA granted Fast Track designation to PIKTOR, an investigational all-oral combo of sapanisertib and serabelisib with paclitaxel for advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations. The article cites a $54.50 consensus 12-month target and Phase 2 PIK-201 topline data expected by year-end 2026.

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates — Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — — Comp

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001829802 0001829802 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21,

Biotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.

Investing.com roundup of US insider trades: Jewett-Cameron (JCTC) 10% owners bought $806k (353,607 shares) June 29; RH director bought 11,388 shares for $1.83m; Faeth Therapeutics CFO bought 13,634 shares for $326k; GitLab CEO bought 4,188 shares for $123k. Sells: Oruka (ORKA) fund sold 3.55m shares for $300m; AMAT CEO sold 78,321 shares ~$55.5m; Airbnb director sold 294,903 shares ~$43.8m; Snowflake director sold 99,900 shares ~$25.1m; Workday owner sold 107,500 shares ~$13.1m.

STEPHENSON BRIAN C (Chief Financial Officer) purchased 13,634 indirectly-held shares of Faeth Therapeutics, Inc. (FTH) at an average of $23.92 ($22.95–$24.98, $0.33M total) across 6 trades over 2026-06-29 to 2026-07-01.

Robert W. Baird upgraded Sensei Biotherapeutics (NASDAQ:FTH) to a “strong-buy” rating, according to Zacks.com. Other firms issued mixed views: BTIG also set “strong-buy,” HC Wainwright initiated with a $60 target, and Weiss Ratings began with a “sell (d-)” rating. FTH opened at $22.87; MarketBeat cites an average “Buy” rating and $58.50 target.